These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10782756)

  • 1. Calcium antagonists and cardiovascular risk in patients with hypertension and Type 2 diabetes mellitus: evidence from the PIUMA Study. Progetto Ipertensione Umbria Monitoraggio Ambulatoriale.
    Verdecchia P; Schillaci G; Reboldi G; Borgioni C; Ciucci A; Porcellati C
    Diabetes Nutr Metab; 1999 Aug; 12(4):292-9. PubMed ID: 10782756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of elevated white blood cell count in hypertension.
    Schillaci G; Pirro M; Pucci G; Ronti T; Vaudo G; Mannarino MR; Porcellati C; Mannarino E
    Am J Hypertens; 2007 Apr; 20(4):364-9. PubMed ID: 17386341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.
    Gress TW; Nieto FJ; Shahar E; Wofford MR; Brancati FL
    N Engl J Med; 2000 Mar; 342(13):905-12. PubMed ID: 10738048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
    Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
    Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up.
    Almgren T; Wilhelmsen L; Samuelsson O; Himmelmann A; Rosengren A; Andersson OK
    J Hypertens; 2007 Jun; 25(6):1311-7. PubMed ID: 17563546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
    Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
    Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using medication history to measure confounding by indication in assessing calcium channel blockers and other antihypertensive therapy.
    Leader S; Mallick R; Roht L
    J Hum Hypertens; 2001 Mar; 15(3):153-9. PubMed ID: 11317198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.
    Kuti EL; Baker WL; White CM
    Curr Med Res Opin; 2007 Jun; 23(6):1239-44. PubMed ID: 17559720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
    Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
    Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium channel blockers in diabetic subjects: innocent at last?
    Zoccali C
    Diabetes Nutr Metab; 1999 Aug; 12(4):249-51. PubMed ID: 10782749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
    Busch M; Franke S; Wolf G; Brandstädt A; Ott U; Gerth J; Hunsicker LG; Stein G;
    Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical characteristics and follow-up of patients attending a hospital hypertension clinic. 10-year experience].
    Valero Capilla FA; Masana Marín L
    An Med Interna; 1999 Oct; 16(10):498-503. PubMed ID: 10603666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium channel blockers and cardiovascular complications in hypertensive diabetics.
    Hardy KJ; Flynn CA
    J Fam Pract; 1998 Jun; 46(6):454-5. PubMed ID: 9638103
    [No Abstract]   [Full Text] [Related]  

  • 15. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction.
    Mancia G
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S17-25. PubMed ID: 15868115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCBs vs ACE inhibitors in patients with diabetes.
    Zamorski MA
    J Fam Pract; 1998 Jul; 47(1):12-3. PubMed ID: 9673598
    [No Abstract]   [Full Text] [Related]  

  • 17. New treatment guidelines for a patient with diabetes and hypertension.
    Mogensen CE
    J Hypertens Suppl; 2003 Mar; 21(1):S25-30. PubMed ID: 12769164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hypertension in chronic kidney disease.
    Toto RD
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety of antihypertensive therapy.
    Grossman E; Messerli FH
    Prog Cardiovasc Dis; 2006; 49(1):16-25. PubMed ID: 16867847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.